Drug Information

Drug (ID: DG01473) and It's Reported Resistant Information

Name	3-Deazaneplanocin
Synonyms	3-Deazaneplanocin; 3-Deazaneplanocin A; 102052-95-9; (1s,2r,5r)-5-(4-amino-1h-imidazo[4,5-c]pyridin-1-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol; 3-Deazaneplanocin,DZNep; 3-Deazaneplanocin-A; UNII-544SH4020S; DZNep; (1S,2R,5R)-5-(4-aminoimidazo[4,5-c]pyridin-1-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol; CHEMBL154745; 544SH4020S; 3-Deaza-neplanocin; c^Neplanocin A; 3-Deazaneplanocin A (DZNep) hydrochloride; 3-Deazaneplanocin A (DZNep; SCHEMBL863851; SCHEMBL12280736; DTXSID30144562; InSolution EZH2 Inhibitor, DZNep; AVS-4275; CEA05295; 3238AH; BDBM50096906; ZINC21290121; AKOS005146283; CS-0357; AC-27393; HY-10442; BRD-K77791657-001-01-1; Q15410156; (-)-1-[(1R,4R,5S)-3-(Hydroxymethyl)-4,5-dihydroxy-2-cyclopenten-1-yl]4-aminoimidazo[4,5-c]pyridine; 3-Cyclopentene-1,2-diol, 5-(4-amino-1H-imidazo(4,5-c)pyridiny-1-yl)-3-(hydroxymethyl)-, (1S-(alpha,2alpha,5beta))- Click to Show/Hide
Structure
Target	.	NOUNIPROTAC	[1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula	2
IsoSMILES	C1=CN=C(C2=C1N(C=N2)[C@@H]3C=C([C@H]([C@H]3O)O)CO)N
InChI	InChI=1S/C12H14N4O3/c13-12-9-7(1-2-14-12)16(5-15-9)8-3-6(4-17)10(18)11(8)19/h1-3,5,8,10-11,17-19H,4H2,(H2,13,14)/t8-,10-,11+/m1/s1
InChIKey	OMKHWTRUYNAGFG-IEBDPFPHSA-N
PubChem CID	73087

Type(s) of Resistant Mechanism of This Drug

EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Click to Show/Hide the Resistance Disease of This Class

Diffuse large B-cell lymphoma [ICD-11: 2A81]

Click to Show/Hide

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
Epigenetic Alteration of DNA, RNA or Protein (EADR)			Click to Show/Hide
Key Molecule: Histone-lysine N-methyltransferase EZH2 (EZH2)				[1]
Molecule Alteration	Missense mutation		p.Y641N (c.1921T>A)	Molecule Info
Sensitive Disease	Diffuse large B-cell lymphoma [ICD-11: 2A81.0]			Disease Info
Experimental Note	Revealed Based on the Cell Line Data
In Vitro Model	Hela cells	Cervix uteri	Homo sapiens (Human)	CVCL_0030
Experiment for Molecule Alteration	Chromatin Immunoprecipitation assay; Western blotting analysis
Experiment for Drug Resistance	Propidium-iodide cell cycle analysis; BrdU-PI cell cycle analysis

References

Ref 1	HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphomaOncotarget. 2015 Mar 10;6(7):4863-87. doi: 10.18632/oncotarget.3120.